Pathway Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Pathway Wealth Management's VRTX Position: Q2 2026 in Review
Pathway Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 11% in Q2 2026, selling an estimated $22.2K and leaving 425 shares worth $211K. The position accounts for 0.15% of the portfolio, ranked #30.
Pathway Wealth Management first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $215K in Q4 2025. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Pathway Wealth Management held 425 shares of Vertex Pharmaceuticals worth $211K as of Q2 2026.
- Pathway Wealth Management sold 50 Vertex Pharmaceuticals shares in Q2 2026, an estimated $22.2K.
- Vertex Pharmaceuticals made up 0.15% of Pathway Wealth Management's portfolio in Q2 2026, its #30 holding.
- Pathway Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- Pathway Wealth Management's Vertex Pharmaceuticals position peaked at $215K in Q4 2025.
- 1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Pathway Wealth Management's 13F filing for Q2 2026, filed 20 Jul 2026.